March 2015

New Product - Triumeq

Triumeq (dolutegravir sodium, abacavir sulfate and lamivudine) contains an integrase inhibitor and two nucleoside reverse transcriptase inhibitors respectively. It is indicated in the treatment of human immunodeficiency virus (HIV) infection in adults and adolescents from 12 years of age who are antiretroviral treatment naïve or are infected with HIV without documented or clinically suspected resistance to any of the three antiretroviral agents (dolutegravir, abacavir or lamivudine) in Triumeq. Triumeq is contraindicated in combination with dofetilide or pilsicainide. Triumeq tablets (dolutegravir 50 mg, abacavir 600 mg, lamivudine 300 mg) are available in packs of 30’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au